)
)
Gyre Therapeutics Investor Relations Material
Latest events
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Gyre Therapeutics Inc
Access all reports
Gyre Therapeutics Inc., formerly known as Catalyst Biosciences, Inc., is a biopharmaceutical company engaged in the development and commercialization of therapies for organ fibrosis and inflammatory diseases. The company's main focus is on the development of Hydronidone (F351), a therapeutic aimed at treating Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis), previously known as Nonalcoholic Steatohepatitis (NASH). The company is headquartered in San Diego, California, and its shares are listed on the NASDAQ.
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
GYRE
Country
🇺🇸 United States